Infection-induced thrombocytosis is a clinically important complication of tuberculosis (TB). 26
Introduction 46
Mycobacterium tuberculosis is the world's most lethal pathogen, causing nearly 2 million deaths each year 1 . The increasing incidence of both multi-and extremely-drug resistant 48 tuberculosis (TB) urgently require the development of therapeutics that overcome the 49 shortcomings of conventional antibiotics. Pathogenic mycobacteria co-opt numerous host 50 pathways to establish persistent infection, and subversion of these interactions with host-51 directed therapies (HDTs) has been shown to reduce the severity of infection in animal 52 models. For example, we have recently shown that mycobacteria induce host angiogenesis 53 and increase host vascular permeability; blockade of either of these processes reduced both 54 caudal vein or trunk of M-222 (tricaine)-anaesthetized 30-48 hpf embryos resulting in a 94 standard infectious dose ~400 fluorescent M. marinum. Embryos were recovered into E3 95 supplemented with 0.036 g/L PTU, housed at 28 °C and imaged on day 5 of infection unless 96 otherwise stated. 97 98
Drug treatments 99
Embryos were treated with vehicle control (DMSO or water as appropriate), 10 µg/ml 100 aspirin, 20 µg/ml tirofiban, 10 µM eptifibatide, or 5 µM warfarin. Drugs and E3 were 101 replaced on days 0, 2, and 4 days post infection (DPI) unless otherwise stated. 102 103
Tail wound thrombosis assay 104
Three day post fertilization (DPF) embryos were treated over-night with anti-platelet drugs. 105
They were anaesthetized, and then a small amount of their tail was removed with a scalpel. 106 All t-tests were unpaired t-tests with Welch's correction. All ANOVA were ordinary one-way 143 ANOVA, comparing the mean of each group with the mean of every other group, using 144 Turkey's multiple comparisons test with a single pooled variance. In cases where data was 145 pooled from multiple experiments, data from each was normalized to its own 146 within-experiment control (usually 'DMSO') before pooling. Outliers were removed using 147 ROUT, with Q=1%. Because the cd41 promoter is active in non-motile thrombocyte precursors within their 160 caudal hematopoietic tissue, we could not conclusively determine if these thrombocytes had 161 actively migrated to and been retained at the site of infection 11 . To determine if zebrafish 162 thrombocytes are recruited to sites of mycobacterial infection, we performed trunk injection 163 of M. marinum in Tg(cd41:GFP) at 3 days post fertilization (DPF), a time point after which 164 mature thrombocytes are in the circulation. Embryos were then imaged at 2, 3, and 4 DPI. 165
Rather than forming a stable and growing clot over a period of days, thrombocytes appeared 166 to form transient associations with sites of infection, and new thrombocytes seemed to be retained at sites of infection in different locations each day ( Figure 1D ). We therefore 168 recorded videos of Tg(cd41:GFP) embryos infected with M. marinum-tomato using a long 169 pass GFP filter to capture bacterial and thrombocyte fluorescence simultaneously. 170
Thrombocytes were most often observed on the edges of granulomas consistent with the 171 location of granuloma-defining macrophages 16 . They also formed short associations with 172 sites of infection, sometimes lasting only 5-10 minutes (Supplementary Video 1). Therefore 173 thrombocyte-granuloma interactions appear to be a conserved feature of mycobacterial 174 infection across species. 175 176 Anti-platelet drugs reduce mycobacterial burden in zebrafish. 177
178
It has previously been reported that aspirin has a host-protective effect during TB infection 17-179 20 . Most of these studies have focused on the fact that aspirin is a broadly acting nonsteroidal 180 anti-inflammatory drug (NSAID) that is known to modulate infection-relevant prostaglandin 181 metabolism 21 . However, aspirin is also a widely-used platelet inhibitor, and we theorized this 182 capacity may also play a role in the drug's effectiveness against TB. 183
184
To test this hypothesis we first confirmed that aspirin's protective effect was seen across 185 species, by treating M. marinum-infected fish with aspirin by immersion. Mycobacterial 186 burden was reduced by approximately 50% in aspirin-treated embryos (Figure 2A) . 187
188
To determine if the anti-platelet effects of aspirin treatment contribute to the reduced 189 mycobacterial burden, we treated M. marinum-infected fish with the platelet-specific, small 190 molecule glycoprotein IIb/IIIa inhibitors, tirofiban or eptifibatide. These drugs do not inhibit 191 platelet activation and de-granulation, but rather inhibit activated platelets from binding to one-another, and to monocytes, via fibrinogen. Treatment with either glycoprotein IIb/IIIa 193 inhibitor phenocopied aspirin by reducing bacterial burden providing direct evidence of a 194 pathological role for thrombocyte activation in the immune response to mycobacterial 195 infection ( Figure 2B To determine if zebrafish thrombocytes are the conserved target for anti-platelet drugs in the 209 zebrafish-M. marinum infection model, we inhibited thrombopoiesis by injection with a 210 morpholino against the thrombopoietin receptor cmpl 11 . Inhibition of thrombopoiesis did not 211 affect the outcome of infection. However, both aspirin and tirofiban treatment failed to 212 reduce bacterial burden in thrombocyte-depleted embryos, demonstrating thrombocytes are 213 the cellular target of this drug in the zebrafish infection model ( Figure 3A-B) . 214 off-target effects in the zebrafish. Therefore, to confirm that disruption of Glycoprotein IIb/IIIa 218 binding alone can reduce bacterial burden, we performed infection experiments in 219
Glycoprotein IIb/IIIa knock-out (KO) transgenic embryos (itga2b mutants). The itga2b sa10134 220 allele caused a dose-dependent reduction in thrombocytes recruited to tail wound clots (Figure 221 S1D), and KO of itga2b significantly reduced bacterial burden ( Figure 3C ). 222
223
Similarly, when we when we addressed the same question using a fibrinogen alpha chain (fga) 224 mutant zebrafish line that does not produce mature fibrinogen, we saw that KO fish had 225 significantly reduced bacterial burden ( Figure 3D ). Furthermore, while tirofiban was able to 226 reduce bacterial burden in fga sufficient mutants, it did not reduce bacterial burden in fga KO. 227 Together these data suggest that tirofiban is reducing bacterial burden by inhibiting binding 228 between glycoprotein IIb/IIIa and fibrinogen. 229 These data suggested clotting could be driven by mycobacterial and may thus contribute to 246 mycobacterial pathogenesis. To test this hypothesis, we treated infected embryos with the 247 anti-coagulant warfarin to prevent clot formation. We did not observe significant changes in 248 bacterial burden, suggesting coagulation itself does not affect bacterial growth within the host 249
Together, these data demonstrate that while coagulation is a consequence of 250 infection driven by a conserved mycobacterial pathogenicity program across host species, the 251 effects of coagulation on mycobacterial pathogenesis vary between host species 6 . 252
253
Thrombocytes increase mycobacterial burden independently of coagulation. 254
255
To assess the contribution of thrombocytes to infection-induced coagulation, we analyzed the 256 formation of FGB-GFP clots in tirofiban-treated Tg(fabp10a:fgb-EGFP) embryos. Tirofiban 257 visibly reduced total clot formation ( Figure 5A ). However, correction for relative bacterial 258 burden suggested that the reduced clot formation was burden-dependent and thrombus 259 formation was not additionally impacted by tirofiban treatment ( Figure 5B ). Therefore, we 260 hypothesized that tirofiban was reducing bacterial burden independently of infection-induced 261 coagulation. To investigate this hypothesis, we again used warfarin, which prevented clot 262 formation during infection and did not affect bacterial burden ( Figure 4C -D and 5C). As 263 expected, the addition of warfarin to our tirofiban treatment model had no effect on the ability of 264 tirofiban to reduce bacterial burden ( Figure 5D ), indicating that tirofiban acts through an 265 independent process. This suggests that the protective effect of tirofiban occurs independently of 266 fibrin clot formation, but requires the presence of soluble fibrinogen. To demonstrate that thrombocyte inhibition exerts a protective effect through boosting 299 macrophage-dependent immunity, we depleted macrophages by injecting clodronate liposomes 300 to deplete macrophages early during granuloma formation at 3 DPI ( Figure 6C ). Macrophage-301 depleted fish were unresponsive to tirofiban treatment demonstrating that pathological 302 thrombocyte activation promotes bacterial growth via interactions with macrophages ( Figure  303 6D). Together these results demonstrate glycoprotein IIb/IIIa inhibitor treatment disrupt 304 pathological thrombocyte-macrophage attachments in mycobacterial granulomas. 305
Conversely, treatment of established infections from 4 to 5 DPI, a time-point when granulomas 318 become organized and necrotic, tirofiban significantly reduced bacterial burden within 24 hours 319 ( Figure 7B ). Together, these data demonstrate the existence of a switch point in granuloma 320 maturity when thrombocytes are either activated or the activation of thrombocytes becomes 321 pathological. 322 323 Co-incident with the appearance of granuloma necrosis at 4 to 5 DPI, we have demonstrated the 324 appearance of foam cells in zebrafish embryo granulomas at this stage of infection 15 . It has 325 previously been shown that platelets accelerate the conversion of macrophages to foam cells 326 in the presence of mycobacteria in vitro 9 . Foam cells are permissive for mycobacterial 327 growth, suggesting a mechanism for infection-induced thrombocyte activation to compromise 328 innate immunity. We therefore hypothesized that thrombocyte inhibition would reduce the 329 conversion of macrophages into foam cells. We investigated this by performing Oil-red O 330 staining to measure lipid accumulation within size-matched granulomas ( Figure 7C) . effect 20 , and a mouse study identified an antagonistic relationship between aspirin and the 361 frontline anti-tubercular drug isoniazid 28 . This lack of consensus may be due to the fact that 362 the NSAID effect of aspirin will affect many cell types and processes important in the 363 heterogeneous host response to mycobacterial infection. Our study expands this literature by 364 delineating a role for glycoprotein IIb/IIIa in compromising the host response to infection. 365
Our study found that coagulation, thrombocytosis, and thrombocyte activation have distinct 367 roles during the pathogenesis of mycobacterial infection of zebrafish. Inhibiting coagulation 368 alone did not significantly reduce bacterial burden, and therefore we considered anti-platelet 369 treatment as a more attractive HDT than anti-coagulant treatment. Although we found lower 370 total clot formation in tirofiban-treated embryos, this was only proportional to bacterial load, 371 suggesting infection-induced coagulation could be independent of infection-induced 372 thrombocyte aggregation. It must be noted that we only measure a simple single end-point in our 
